Generic placeholder image

Recent Patents on Regenerative Medicine


ISSN (Print): 2210-2965
ISSN (Online): 2210-2973

Review Article

Review of Patents and Commercial Opportunities Involving Mesenchymal Stromal Cells (MSCs) Therapies in Osteoarthritis

Author(s): Sowmya Viswanathan and Alejandro Gomez-Aristizabal

Volume 4, Issue 1, 2014

Page: [1 - 15] Pages: 15

DOI: 10.2174/2210296504666140307010938

Price: $65


Osteoarthritis (OA) is a degenerative joint disease that affects cartilage, subchondral bone, the synovium and synovial fluid and has limited treatment options. With an ageing population and growing health economic costs, novel treatment options for OA are urgently needed. Mesenchymal stromal cells (MSCs) with their demonstrated abilities to modulate pain and inflammation, and with their ability to contribute to chondrocyte differentiation and proliferation are therefore being investigated globally for their potential to provide novel treatment options for OA patients. In this paper, we review the preclinical studies and early clinical trials, and the patent landscape for the use of MSCs for the treatment of OA.

Keywords: Cartilage, clinical trials, companies, immunoregulation, mesenchymal stromal cells, osteoarthritis, therapies.

Next »

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy